Jul 11,2022

Better Therapeutics Announces Publication of the Rationale, Design and Baseline Characteristics Manuscript for Type 2 Diabetes Pivotal Trial of BT-001, a Novel Prescription Digital Therapy, in Clinical Cardiology

The study represents a first-in-class randomized, controlled clinical trial of a prescription digital therapeutic (PDT) for the treatment of T2D and is expected to support the filing of a de novo classification request with the U.S. Food and Drug Administration (FDA) in the third quarter of 2022.

CLINICAL STUDY

#dtx

View Analyst & Ambassador Comments
Go to original news
Jul 12,2022

Tandem Diabetes Care to Announce Second Quarter 2022 Financial Results on August 3, 2022

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its second quarter 2022 results after the financial markets close on Wednesday, August 3, 2022.

View Analyst & Ambassador Comments
Go to original news
Jul 13,2022

Perioperative Fully Closed-Loop Insulin Delivery in Patients Undergoing Elective Surgery: An Open-Label, Randomized Controlled Trial

Perioperative management of glucose levels remains challenging. Teh researchers aimed to assess whether fully closed-loop subcutaneous insulin delivery would improve glycemic control compared with standard insulin therapy in insulin-requiring patients undergoing elective surgery.

CLINICAL STUDY

#closed loop

View Analyst & Ambassador Comments
Go to original news
Jul 13,2022

Insights on the Blood Glucose Test Strips Global Market to 2027 - by Type, Technology, Distribution Channel, End-user and Region

The global blood glucose test strips market reached a value of US$ 10.53 Billion in 2021. Looking forward, the publisher expects the market to reach a value of US$ 17.57 Billion by 2027, exhibiting a CAGR of 8.91% during 2021-2027.

View Analyst & Ambassador Comments
Go to original news
Jul 13,2022

Glooko Launches Diabetes Medical Education Academy in Ireland

Glooko announced, in partnership with the Diabetes Technology Network (DTN)/Association of British Clinical Diabetologists (ABCD), the expansion into Ireland of Academy, the company’s online medical education program for clinicians who treat people with diabetes.

View Analyst & Ambassador Comments
Go to original news
Jul 15,2022

New Data Shows Teladoc Health’s Integrated Chronic Care Solutions Deliver Improved Health Outcomes

Teladoc Health (NYSE: TDOC), the global leader in whole-person virtual care, today released new findings showing that managing multiple chronic conditions with a single, integrated approach leads to better control of A1c, systolic blood pressure and weight better than any diabetes, hypertension or weight control program alone.

CLINICAL STUDY

#virtual care

View Analyst & Ambassador Comments
Go to original news
Jul 19,2022

New Study Links One Drop's AI-Powered Blood Glucose Forecasts to Better Engagement and Diabetes Outcomes

One Drop announced outcomes from a retrospective cohort study published in the Journal of Medical Internet Research (JMIR) on the effects of its novel AI-powered blood glucose (BG) forecasting feature. The study focuses on indicators of glycemic control and health data logging in adults with type 2 diabetes (T2Ds) using the award-winning One Drop digital health platform.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jul 20,2022

ABBOTT REPORTS SECOND-QUARTER 2022 RESULTS AND RAISES FULL-YEAR EPS GUIDANCE

In Diabetes Care, FreeStyle Libre sales were approximately $1.1 billion in the quarter, which represents sales growth of 18.7 percent on a reported basis and 25.6 percent on an organic basis.

View Analyst & Ambassador Comments
Go to original news
Jul 20,2022

The Influence of Digital Affinity on the CGM System Choice by People With Type 1 Diabetes

The aim of the study was to investigate the influence of digital affinity on the CGM use and the choice of a particular system.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Jul 20,2022

Use of Continuous Glucose Monitors by People Without Diabetes: An Idea Whose Time Has Come?

Continuous glucose monitor (CGM) systems were originally intended only for people with diabetes. Recently, there has been interest in monitoring glucose concentrations in a variety of other situations. As data accumulate to support the use of CGM systems in additional states unrelated to diabetes, the use of CGM systems is likely to increase accordingly.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES